STOCKS TELEGRAPH

Tag: NASDAQ:ACON

  • Aclarion (ACON) Shares Surge In Pre-Hour Trading Amid Key Healthcare Deal

    Aclarion (ACON) Shares Surge In Pre-Hour Trading Amid Key Healthcare Deal

    The stock value of Aclarion, Inc. (NASDAQ: ACON) surged by 90.15% to $6.37 as of the most recent premarket session. This increase follows a strategic alliance that might greatly increase the company’s power and reach in the healthcare industry.

    Introducing Nociscan to Southern California

    Aclarion has signed a business contract with San Diego, California-based Scripps Health, a preeminent healthcare organization. A significant milestone for the firm will be reached when Aclarion’s Nociscan technology is brought to the area under the terms of this agreement.

    Patients, especially those looking for relief from persistent low back pain, will now have access to Nociscan from Scripps Health, which is known for being the biggest healthcare provider in San Diego. Scripps Green Hospital will provide Nociscan, giving patients access to improved diagnostic tools and more precise treatment planning.

    Resolving Prolonged Low Back Pain with Creative Approaches

    Approximately 266 million individuals worldwide suffer from chronic low back pain (cLBP), making it a serious global health concern. The innovative, non-invasive Nociscan technology from ACON stands out as a reaction to this. It uses a Software-as-a-Service (SaaS) paradigm to assist doctors in differentiating between lumbar spine discs that cause pain and those that don’t.

    Nociscan provides doctors with crucial information that can direct treatment decisions by scientifically quantifying chemical biomarkers associated with disc pain. Nociscan provides priceless insights that can enhance patient outcomes when combined with other diagnostic techniques.

    The Contribution of Scripps Health to Improving Spine Care

    Over half a million patients are treated each year by Scripps Health, a nonprofit healthcare organization that includes five hospitals and 19 outpatient clinics. Nociscan will be included into clinical practice and current research studies by the system, which is known for being a pioneer in clinical research and teaching.

    This effort is being led by Scripps orthopedic physician Dr. Robert Eastlack. The system will be able to provide millions of Southern Californians with enhanced diagnostic alternatives thanks to his experience and his substantial contributions to the field of spine care research, which will further advance the field of spine care.

  • Aclarion (ACON) Shares Rebound in After-Market Trading

    Aclarion (ACON) Shares Rebound in After-Market Trading

    Shares of Aclarion, Inc. (NASDAQ: ACON) are seeing a recovery today, partially recovering a previous-session drop. As of the last premarket check, ACON stock was trading 8.36% up at $3.50. Even if there was no immediate news that caused the price to change, recent developments could have contributed to the resurgence of investor interest.

    Cutting Edge Technology on Display at the 2025 Spine Summit

    Distinguished orthopedic surgeon Dr. Nicholas Theodore highlighted the revolutionary potential of Aclarion’s in-house technology, NOCISCAN, at the company’s recent participation in the 2025 Spine Summit last week. By combining augmented intelligence with magnetic resonance (MR) spectroscopy, this cutting-edge tool seeks to transform spine surgery by offering noninvasive, objective diagnostic insights.

    Dr. Theodore emphasized how NOCISCAN improves the accuracy of chronic low back pain (cLBP) diagnosis. With approximately 266 million people worldwide suffering from degenerative spine disease and low back pain, Aclarion’s technology offers a critical tool for identifying pain sources that are undetectable through traditional imaging.

    ACON’s Industry Standing and Peer Comparisons

    ACON currently holds a score of 34 on our screener and is categorized within the Medical Healthcare Information Services industry. To provide a broader market perspective, we have compiled a list of peer stocks that have achieved higher scores and received “Buy” analyst recommendations. This exclusive compilation can be accessed through our ST screener link, offering investors valuable insights into potentially stronger investment opportunities.

    Aclarion Strengthening its Portfolio

    Along with its technological innovations, Aclarion recently received a Notice of Allowance for its 24th granted U.S. patent from the United States Patent and Trademark Office (USPTO). This new invention expands the application to detect propionic acid (PA) throughout the body, whereas earlier patents concentrated on employing MR spectroscopy to detect PA in spinal discs.

    This development strengthens Aclarion’s position as a pioneer in cutting-edge medical diagnostics by improving its capacity to pinpoint possible infection and pain origins. Aclarion continues to lead the way in spine diagnostics, opening the door for better patient outcomes and wider clinical use with its innovative technology, ongoing patent acquisitions, and increasing industry recognition.

  • Investor Confidence Grows As Aclarion (ACON) Secures Funding For CLARITY Trial

    Investor Confidence Grows As Aclarion (ACON) Secures Funding For CLARITY Trial

    Following the announcement that it has secured full financing for its crucial CLARITY trial, Aclarion, Inc. (NASDAQ: ACON) has seen a notable increase in the value of its shares. ACON shares have risen 5.56% to $7.02 as of the most recent market report. This encouraging development highlights investor faith in the business’s creative method of identifying and managing persistent low back pain.

    Developing AI-Powered Diagnostics to Advance Spine Surgery

    Aclarion is a healthcare technology company that helps doctors identify the exact site of persistent low back pain by using unique augmented intelligence (AI) algorithms and cutting-edge biomarkers.

    The CLARITY experiment, which is an essential step in proving the clinical and financial benefits of the company’s Nociscan technology in spine surgery, will be completed thanks to the cash that has been received. This development has the potential to broaden payer coverage and revolutionize treatment strategies for chronic low back pain.

    The Clarity Trial: A Seminal Investigation in the Management of Back Pain

    Dr. Nicholas Theodore of Johns Hopkins is the primary investigator of the prospective, randomized, multicenter clinical research known as the CLARITY trial. To confirm Nociscan’s effectiveness in enhancing surgical results for patients with persistent low back pain, 300 patients from various medical facilities will be enrolled in the study. By utilizing peer-reviewed data, the trial seeks to substantiate Nociscan’s ability to enhance surgical precision by accurately identifying pain-inducing discs.

    Addressing a Global Health Challenge with Nociscan

    Chronic low back pain (cLBP) is a widespread health concern, affecting approximately 266 million individuals globally due to degenerative spine disease. Aclarion’s Nociscan platform is the first evidence-based, noninvasive SaaS solution designed to help physicians differentiate between painful and nonpainful lumbar discs.

    By objectively measuring chemical biomarkers associated with disc pain, Nociscan offers critical insights that enhance diagnostic accuracy. Clinical studies indicate a 97% surgical success rate one year post-procedure when all Nociscan-identified pain-positive discs are treated.

    Bullish Market Standing for Aclarion

    Its strong market performance has positioned ACON with a “Bullish” rating on our screener within the Medical-Healthcare Information Services sector. Investors can explore peer stocks with similar trajectories via our ST screener link for further market insights.

  • Aclarion (ACON) Stock Rises Following Strategic Partnership

    Aclarion (ACON) Stock Rises Following Strategic Partnership

    A surge in Aclarion, Inc. (NASDAQ: ACON) stock is currently dominating the US stock landscape, with the current session reporting a remarkable 29.15% increase, reaching $3.95. This upswing follows the revelation of a significant partnership, marking a pivotal moment for Aclarion.

    Today, Aclarion (ACON) officially disclosed the execution of a strategic partnership agreement, formalizing a prior non-binding Letter of Intent (“LOI”) with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

    The collaboration harnesses ATEC’s AlphaInformatiX platform’s unique structural insights and combines them with Aclarion’s Nociscan solution, leveraging innovative biomarker data to identify potentially painful discs. This integration aims to provide surgeons with an unprecedented, comprehensive platform, enhancing clinical outcomes and reducing procedural costs for chronic low back pain (cLBP) patients.

    The agreement outlines a multi-step strategic partnership wherein ATEC and Aclarion commit to collaboratively identify key opinion leader (KOL) surgeons for Nociscan technology evaluation. Surgeon feedback will guide clinical assessments, evaluating the utility of Nociscan alongside EOS imaging, the foundation of ATEC’s AlphaInformatiX platform.

    Upon positive outcomes, ATEC and Aclarion plan to co-market Nociscan in targeted markets. In exchange for exclusive distribution rights, Aclarion will grant ATEC select access to its surgeon network for Nociscan evaluation and advancement within an integrated procedural solution.

    Both companies have already designated internal leaders and resources for the initial phase, emphasizing the significance of biochemical markers in progressing toward shared objectives of advancing technologies in spine patient care. Nociscan, Aclarion’s proprietary decision-support tool, represents the first evidence-supported SaaS platform enabling physicians to noninvasively differentiate between painful and nonpainful discs in the lumbar spine.

    By objectively quantifying chemical biomarkers associated with disc pain, Nociscan, when integrated with other diagnostic tools, offers crucial insights into the precise location of a patient’s low back pain, empowering physicians to optimize treatment strategies with clarity.